SEC For	m 4 FORM	4	UNITED) STA	TE	S SE			ES ANE			NGE	COM	MIS	SION				
Section 16. Form 4 or Form 5 obligations may continue. See					ed pur	d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									ΗP	OMB Estim	OMB APPRON OMB Number: Estimated average burder hours per response:		3235-0287
1. Name and Address of Reporting Person* <u>CLEMENS PETER A</u>						2. Issuer Name and Ticker or Trading Symbol <u>ACURA PHARMACEUTICALS, INC</u> [ACUR]									k all applic Directo Officer	able)	10% Owner e title Other (speci		wner
(Last)(First)(Middle)C/O ACURA PHARMACEUTICALS, INC.616 N. NORTH COURT, SUITE 120						3. Date of Earliest Transaction (Month/Day/Year) 01/03/2023									below)	Senior V	/P &	below) CFO	
(Street) PALATINE IL 60067					. 4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)									ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	,	(Zip)	Doriy		. 5			quirod	Die	nocodia	f or P	nofici		Ownod				
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/E)					action	n 2 E ear) i	2A. Deemed Execution Date, if any (Month/Day/Yea		3. Transaction Code (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3,			or 5. Amoun and Securities Beneficia Owned Fo		nt of 6. 0 s Form Illy (D) ollowing (I) (I		Ownership rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	nount (A) or (D) P		e	Reported Transacti (Instr. 3 a	ion(s)			(Instr. 4)
Common Stock 01/03					3/202			M ⁽¹⁾		40,00	0 A		(2) 505,4		430 ⁽³⁾	30 ⁽³⁾ D			
		-	Table II - I						uired, D s, option						Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemee Execution I if any (Month/Day	Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)			3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s illy g	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amou or Numb of Share	er					
Restricted Stock Unit (2017 Plan)	\$0.01 ⁽²⁾	01/03/2023			М		40,000		(5)		(5)	Common Stock	40,00	00	(4)	40,00	0	D	

Explanation of Responses:

1. Represents exchange of restricted stock units.

2. Par value of \$.01 must be paid by Reporting Person upon exchange of Restricted Stock Units for stock.

3. Does not include Restricted Stock Units.

4. Not Applicable.

5. 120,000 Restricted Stock Units were granted on December 11, 2018 and were 100% vested on December 11, 2019. Distributions in respect of this vested Restricted Stock Units will be made in three equal installments in each of 2021, 2022, and 2023 or earlier upon a qualifying change of control which also meets certain criteria of Section 409A of the Internal Revenue Code.

<u>/s/ Peter A. Clemens</u> 01/05/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.